E. Seeman, et al., “Present and Future of Osteoporosis Therapy,” Bone, vol. 17, No. 2 Supplement, pp. 23S-29S, Aug. 1995. |
D. D. Thompson, et al., “Droloxifene does not Blunt the Bone Anabolic Effects of Prostaglandin E2 (PDE2) but Maintains the PDE2 Restored Bone in Osteopenic Rats,” Journal of Bone and Mineral Research, vol. 11, S1, p. S95, Aug., 1996. |
Pienta, Kenneth J., et al., “A Common Set of Nuclear Matrix Proteins in Prostate Cancer Cells,” The Prostate, 23, pp. 61-67, 1993. |
Neubauer, Blake Lee, et al., Lilly Research Laboratories, “Endocrine and Antiprostatic Effects of Raloxifene (LY156758) in the Male Rat,” The Prostate, 23, pp. 245-262, 1993. |
Martindale, The Estra Pharmacopia, The Parm. Press, London, pp. 477 and 500, 1993. |
Cheng et al., Bone, vol. 17, No. 4 (suppl.), pp. 329s-334s (1995). |
Kudo et al., Journal of Endocrinology, vol. 150, pp. 223-229 (1996). |
Fournier et al., Journal of Enmdocrinology, vol. 150, pp. 275-285 (1996). |
Ke et al., Bone and Mineral, vol. 19, pp. 45-62 (1992). |
Kimmel et al., Osteoporosis, vol. 20, No. 3, pp. 735-758 (1994). |